Readers of Clinical Pharmacist occasionally write to the editor to air their views on the journal's content or on various aspects of pharmacy practice. Here we link you to published correspondence, incorporated into the discussion area of PJ Online. We encourage readers to post comments on our content online or address their correspondence to the editor for publication (firstname.lastname@example.org)
We note the recent COLUMNIST piece by Chris Dixon extolling the benefits of a non-medical prescriber (NMP) forum (Clinical Pharmacist 2013;5;28). We would like to endorse this approach, and also let readers know about our own experience.
We are writing to tell readers about a novel initiative from the Midlands Critical Care Networks pharmacists group. We have devised a comprehensive, transferable educational tool to facilitate the training of aspiring band 7 critical care pharmacists.
As a former professional doctorate student, I should like to extend the discussion (Clinical Pharmacist 2012;4:139 and 2012;4:154) to confirm that there is indeed a multiprofessional doctorate programme available which (for pharmacists) leads to the award of DPharm.
I was interested to read the report by Kate Towers about measuring pharmacy services in the June issue of Clinical Pharmacist (2012;4:153). I quote Winston Churchill when I say: “Those who do not learn from history are doomed to repeat it.”
The Career Development article by Ellen Schafheutle and colleagues on doctoral study (Clinical Pharmacist 2012;4:139) is to be warmly welcomed for showing pharmacists possible routes for career development that extend beyond first and second degrees
I noticed that the article on inflammatory bowel disease (IBD) management in the March 2011 edition of Clinical Pharmacist (2011;3:78) does not mention the National Institute for Health and Clinical Excellence’s clinical guideline on surveillance
On behalf of the College of Mental Health Pharmacy and in support of Depression Awareness Week (11–17 April), organised by Depression Alliance, we urge pharmacists in all areas of healthcare to be involved in supporting people with depression
I should like to update some important information from a recently published article in Clinical Pharmacist. The Clinical focus article, "Chronic kidney disease: managing the complications", states that the National Institute for Health and Clinical Excellence recommends that the treatment of CKD-related anaemia should aim to maintain stable haemoglobin (Hb) levels of 10.5–12.5g/dl for adults
I am writing to let you know that I have found that the "reflective questions" from the Career development?article on reflective practice by Katy Morris and colleagues provide illuminating food-for-thought for my continuing professional development
I read with interest the recent Clinical Focus article on the management of burns, which identified irrigation with water as first aid for chemical burns. It occurred to me that we may need to consider removing contaminated clothing before irrigation
The HIV Pharmacy Association of the UK (HIVPA) is encouraging all pharmacists and technicians with an interest in HIV to join our network, which provides support and training resources
Glomerular filtration rate (GFR) is widely accepted as the preferred index for defining kidney function and chronic kidney disease (CKD)
In your Editor’s Choice column in the December (2009) issue of Clinical Pharmacist (2009;1:466), you have seen fit to dismiss my presentation at the Guild of Healthcare Pharmacists procurement and distribution interest group symposium as my “personal Christmas list, rather than from plans set in stone by those working to develop the professional body”.
We would like to share with readers of Clinical Pharmacist our experience of an audit that led to a reduction in perioperative intramuscular (IM) injections of analgesics and antiemetics, the prescribing of which we deemed inappropriate.
Maxillofacial surgeons are concerned that doctors (GPs and those in hospitals) are starting patients on bisphosphonates without considering, let alone doing, an initial screen of dental health and referral of at-risk patients to a dentist for a full assessment before prescribing. There is a role for pharmacists in stressing the need for patients to be screened for dental problems before bisphosphonates are prescribed.
It seems reasonable to use either eGFR or calculated creatinine clearance to guide dosing as long as the same estimate is used consistently during a particular course of treatment.
My colleagues and I read with interest the recent Practice Tools on “How to manage breakthrough pain”. It is encouraging to see that the significance of breakthrough pain and its management is being highlighted. The author’s suggestion does not seem to be supported by guidance provided in the recent National Patient Safety Agency rapid response report “Reducing dosing errors with opioid medicines” (2008).
Medicines have moved into more complex biological molecules and now pharmacists are being given the opportunity to use cheaper versions of these branded medicines. They are more complex and based on biotechnology, yet the arguments being put forward by manufacturers of originator products have a familiar ring to them.
We read with interest the article by Langford and colleagues (Hospital Pharmacist 2008;15:60) describing the development of a tool to assess the risk to healthcare staff from handling monoclonal antibodies (MABs). We disagree with the level of risk the authors of the article assign to omalizumab, and the basis of their conclusions requires some comment.
Citation: The Pharmaceutical Journal URI: 11002427
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com